Peg-asparaginase for acute lymphoblastic leukemia

Expert Opinion on Biological Therapy

Volumn 10, Issue 5, 2010, Pages 833-839

  Rytting, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Pegylated asparaginase; Toxicity; Young adult

Indexed keywords

ANTHRACYCLINE; ANTIFUNGAL AGENT; ANTITHROMBIN; ASPARAGINASE; ASPARAGINASE MACROGOL; ASPARAGINE; CORTICOSTEROID; METHOTREXATE; PREDNISONE; STEROID; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD BRAIN BARRIER; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; ESCHERICHIA COLI; EVENT FREE SURVIVAL; HUMAN; LIVER TOXICITY; MONOTHERAPY; PANCREATITIS; REVIEW; THROMBOSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ASPARAGINASE; DRUG HYPERSENSITIVITY; HUMANS; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951109481     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712591003769808     Document Type: Review

References (33)

1. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009;27(6):911-18 erratum in 27(15):2574
2. Ribera J, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol 2008;26(11):1843-1849
3. Silverman L, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1985) Leukemia 2000;14(12):2247-2256
4. Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand? Expert Opin Biol Ther 2009;9(1):111-119
5. Fu C, Sakamoto KM. PEG-asparaginase. Expert Opin Pharmacother 2007;8(12):1977-1984
6. Avramis V, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokin 2005;44(4):367-393
7. Asselin B, Whitin JC, Coppola D, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11:1780-1786
8. Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961 J Pediatr Hematol Oncol 2004;26(6):333-335
9. Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007;110(1):103-111
10. Pinheiro JP, Wenner K, Escherich G, et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2500 IU/m2 PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer 2006;46:18-25
11. Pinheiro JP, Muller HJ, SchwabE D, et al. Drug monitoring of low-dose PEG-asparaginase (Oncospar TM) in children with relapsed acute lymphoblastic leukaemia. Br J Hematol 2001;113:115-119
12. Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica 2006;91(1):24-31
13. Hawkins D, Park JR, Thomson BG, et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004;10:5335-5341
14. Dinndorf P, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (oncospar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 2007;12(8):991-998
15. Wenner Ka, Vieira Pinheiro JP, Escherich G, et al. Asparagine concentration in plasma after 2,500 IU/m2 PEG-asparaginase i.v. children with acute lymphoblastic leukemia. Klin Padiatr 2005;217(6):321-326
16. Taylor CW, Dorr RT, Fanta P, et al. A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginae in patients with advanced solid tumors. Cancer Chemother Pharmacol 2001;(47):83-88
17. Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia; results from a single agent window study. Leukemia 2008;22:1665-1679
18. Aguayo A, Cortes J, Thomas D, et al. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 1999;86(7):1203-1209
19. Ettinger LJ, Kurtzberg J, Vôute PA, et al. An open-label, multicenter study of polyethylene glycol-L-asparaginase of the treatment of acute lymphoblastic leukemia. Cancer 1995;75:1176-1181
20. Kurtzberg J. Moore JO, Sandierg D, et al. A phase II study of polyethylene glycol (PEG) conjugated L-asparaginase in patients with refractory acute leukemia. Proc of AACR 1988;29:848
21. Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study. Blood 2000;96(5):1709-1715
22. Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007;109(7):2744-2750
23. Goekbuget N, Baumann A, Beck J, et al. PEG-asparaginase in adult acute lymphoblastic leukemia (ALL): efficacy and feasibility analysis with increasing dose levels. ASH Annual Meeting Abstracts. Blood 2008;112:302
24. Rytting M, Earl M, Douer D, et al. Toxicities in adults with acute lymphoblastic leukemia (ALL) treated with regimens using pegasparaginase. Blood (ASH annual meeting abstracts) 2008;112:1924
25. Wetzler M, Sanford B, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: cancer and leukemia group B study 9511. Blood 2009;109(10):4164-4167
26. Silverman L, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber consortium protocol 91-01. Blood 2001;97:1211-1218
27. Avramis V, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002;99:1986-1994
28. Asselin BL, Kreissman S, Coppola DJ, et al. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1999;21(1):6-12
29. Graham M. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003;55:1293-1302
30. Rosen O, Muller HJ, Gokbuget N, et al. Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. Br J Haematol 2003;123(5):836-841
31. Storring J, Minden M, Kao S, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Hematol 2009;146:76-85
32. Nowak-Gottl U, Kenet G, Mitchell L. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiolgy, diagnosis, prevention and treatment. Best Pract Res Clin Haematol 2009;22(1):103-114
33. Grace RF, Dahlberg S, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in pediatric and acute patients with acute lymphoblastic leukemia treated on the Dana-Farber Cancer Institute (DFCI) Consortium Protocols. [Abstract 3073], 51st ASH Annual Meeting and Exposition; 2009